Hap Trading LLC Has Cut Position in Intercept Pharmaceuticals In (ICPT) by $7.65 Million

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) LogoInvestors sentiment decreased to 1.84 in 2019 Q2. Its down 0.02, from 1.86 in 2019Q1. It fall, as 24 investors sold ICPT shares while 34 reduced holdings. 28 funds opened positions while 79 raised stakes. 24.97 million shares or 33.57% less from 37.59 million shares in 2019Q1 were reported. Jefferies Grp accumulated 30,620 shares or 0.02% of the stock. State Of Wisconsin Inv Board invested in 0.01% or 31,800 shares. Credit Agricole S A holds 0.07% or 17,000 shares. Sei Invests Communication holds 6,505 shares or 0% of its portfolio. Qs Invsts Limited Liability has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Sg Americas Ltd Liability Co owns 3,207 shares. Ameriprise Incorporated has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 126,984 shares. Invesco Ltd owns 12,790 shares. Huntington Bancshares owns 50 shares or 0% of their US portfolio. First Trust Advsr Ltd Partnership accumulated 1.09 million shares. 736 are owned by Fifth Third National Bank. Jennison Associate Ltd Llc holds 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 181,748 shares. Mackay Shields Limited Liability Company, New York-based fund reported 22,126 shares. Us Bancshares De accumulated 0% or 29 shares. Price T Rowe Associate Inc Md reported 194,573 shares or 0% of all its holdings.

Hap Trading Llc decreased its stake in Intercept Pharmaceuticals In (ICPT) by 87.4% based on its latest 2019Q2 regulatory filing with the SEC. Hap Trading Llc sold 96,838 shares as the company’s stock declined 26.77% . The institutional investor held 13,962 shares of the health care company at the end of 2019Q2, valued at $1.11M, down from 110,800 at the end of the previous reported quarter. Hap Trading Llc who had been investing in Intercept Pharmaceuticals In for a number of months, seems to be less bullish one the $2.26B market cap company. The stock increased 1.53% or $1.04 during the last trading session, reaching $69.11. About 485,527 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 29.32% since September 13, 2018 and is downtrending. It has underperformed by 29.32% the S&P500.

Hap Trading Llc, which manages about $1.30 billion US Long portfolio, upped its stake in Gilead Sciences Inc (NASDAQ:GILD) by 118,141 shares to 141,741 shares, valued at $9.58 million in 2019Q2, according to the filing. It also increased its holding in Ishares Tr (Call) (LQD) by 2.45 million shares in the quarter, for a total of 3.49M shares, and has risen its stake in Ally Finl Inc (NYSE:ALLY).

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on October, 30. They expect $-2.33 EPS, down 6.88 % or $0.15 from last year’s $-2.18 per share. After $-2.28 actual EPS reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 2.19 % negative EPS growth.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Globenewswire.com which released: “Intercept Pharmaceuticals Announces Pricing of Offerings of Common Stock and Convertible Senior Notes due 2026 – GlobeNewswire” on May 10, 2019, also Seekingalpha.com with their article: “ICPT, ORPN and NAVI among premarket gainers – Seeking Alpha” published on February 19, 2019, Seekingalpha.com published: “Intercept Pharma EPS beats by $0.33, beats on revenue – Seeking Alpha” on August 07, 2019. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Finance.Yahoo.com and their article: “Investors Who Bought Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Five Years Ago Are Now Down 79% – Yahoo Finance” published on August 08, 2019 as well as Nasdaq.com‘s news article titled: “Noteworthy Wednesday Option Activity: ICPT, MHK, PANW – Nasdaq” with publication date: April 10, 2019.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 4 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Intercept Pharmaceuticals has $18600 highest and $8500 lowest target. $116’s average target is 67.85% above currents $69.11 stock price. Intercept Pharmaceuticals had 8 analyst reports since April 12, 2019 according to SRatingsIntel. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Buy” rating given on Wednesday, September 4 by Citigroup. The firm earned “Hold” rating on Monday, June 24 by Stifel Nicolaus. The stock has “Overweight” rating by Cantor Fitzgerald on Thursday, August 8. The stock has “Market Perform” rating by Wells Fargo on Friday, April 12.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.